The best way to invest in
Genomics
Invest actively in companies leading the genomics revolution - from DNA sequencing and gene editing to molecular diagnostics. Genomics has the potential to transform medicine, agriculture, and materials science through the understanding and manipulation of genetic information.
Read more
-14.4%* 5Y annualised returns
35 genomics and gene editing companies
Sign up and invest with free buy orders
We’re licensed by the Securities Commission Malaysia (Licence eCMSL/A0352/2018)
RETURNS DATA
Invest in the companies decoding the future of human health
1 Year Returns
Loading...
Loading...
Loading...
Disclaimer
Create your Genomics portfolio
StashAway ETF Explorer is the smart way to invest in 90+ global asset classes, including Genomics.
It's cost-effective
- Start investing today to get unlimited free buy orders for your next month.
- After, it's only $1.99 USD per buy or sell order, excluding SST.
- No additional management fee, no matter how much you invest.
It's simple
- Build your portfolio in as little as 1 minute.
- Automate recurring investments for ease of mind.
- No minimum balance, no lock-ins, and high liquidity mean you can access your funds anytime.
It's intelligent
- Our investment team analyses thousands of ETFs to identify cost-efficient, tax-efficient, and well-managed options.
- We swap underlying ETFs if a better alternative surfaces, saving you more over time.
It's cost-effective
- Start investing today to get unlimited free buy orders for your next month.
- After, it's only $1.99 USD per buy or sell order, excluding SST.
- No additional management fee, no matter how much you invest.
It's simple
- Build your portfolio in as little as 1 minute.
- Automate recurring investments for ease of mind.
- No minimum balance, no lock-ins, and high liquidity mean you can access your funds anytime.
It's intelligent
- Our investment team analyses thousands of ETFs to identify cost-efficient, tax-efficient, and well-managed options.
- We swap underlying ETFs if a better alternative surfaces, saving you more over time.
GET STARTED WITH FREE BUY ORDERS
Own genomics stocks with one investment
Invest in the companies rewriting the future of human health
Asset Class Overview
Genomics Snapshot
Key information across returns, asset class profile, and investment details.
Returns
Annualised since inception
+7.23%
Since 31 October 2014
5-year annualised
-14.37%
Since 30 June 2021
1-year annualised
+69.57%
Since 30 June 2025
Year-to-date
+40.11%
Since 2026
Positive years since inception
45.45%
of calendar years
Fund Profile
Asset type
Equities
Fund inception
2014
Fundamentals
Expense ratio
0.75%
Annual ETF expense ratio
1-year dividend yield
-
Trailing 12-month yield
Currency denomination
USD
US Dollar
Disclaimer
RETURNS DATA
Annual returns since 2014
Growth driven by leading genomics and gene editing companies
Did you know?
The cost of sequencing a human genome has fallen from $3 billion in 2003 — when the Human Genome Project completed its first sequence — to under $200 today, a cost reduction faster than Moore's Law. Gene editing technologies like CRISPR-Cas9 now allow scientists to make precise changes to DNA with a level of accuracy and simplicity that was unimaginable a decade ago, opening the door to potential cures for inherited diseases, new cancer therapies, and engineered agricultural products. The global genomics market is projected to grow from approximately $27 billion in 2023 to over $100 billion by 2030, driven by diagnostics, therapeutics, and agricultural applications.
PORTFOLIO BREAKDOWN
Sector exposure
Consumer, Non-cyclical
96.8%
Technology
2.0%
Industrial
0.9%
Government
0.2%
Source: Bloomberg. Weights are approximate and subject to change on index rebalance.
PORTFOLIO BREAKDOWN
Geographic exposure
EXPLORE MORE
Other asset classes available
Other investors who viewed Genomics also explored these
